This panel discussion will cover considerations for manufacturing make vs. buy decisions (internal vs. outsourced manufacturing) for cell and gene therapies. Panelists will consist of executives from companies responsible for manufacturing these innovative therapies. Cell and gene therapy products present significant manufacturing challenges (cost, complexity, quality, lead times) that can be bottlenecks in the overall development timeline; the decision to outsource manufacturing vs. bringing manufacturing in-house impacts these challenges significantly and in diverse ways. The financial implications of the make vs. buy decision, and the timing of that decision may be critical and present trade-offs for achieving critical company milestones and maintaining adequate funding for early development activities. Attendees will hear the perspectives from different companies that have wrestled with this decision and will gain a deeper appreciation for the considerations involved.